Journal
ARTHRITIS & RHEUMATOLOGY
Volume 68, Issue 2, Pages 299-311Publisher
WILEY
DOI: 10.1002/art.39501
Keywords
-
Categories
Funding
- NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases) [U01-AR-055057, K24-AR-063120]
- Canadian Institutes of Health Research (Clinician Scientist Award)
- Bristol-Myers Squibb
- Cytori
- EMD Serono
- Genkyotex
- GlaxoSmithKline
- Gilead
- Medac
- Sanofi-Aventis
- Bayer
- Genentech/Roche
- Actelion
- United Therapeutics
- Pfizer
- Boehringer-Ingelheim
- Biogen Idec
- FibroGen
- Novartis
- Celgene
- DART
- InterMune
- Sigma Tau
- ChemoCentryx
- Sanofi
- Medtelligence
- CSL Behring
- Sanofi-Aventis/Genzyme
- Medimmune
- Behring
- Inventiva
- Sanofi/Genzyme
- Servier
- UCB
- Roche
- Ergonex
- United BioSource
- Biovitrium
- MSD
- Janssen
- AbbVie
- Amgen
- Versus Arthritis [20719] Funding Source: researchfish
Ask authors/readers for more resources
Objective. Early diffuse cutaneous systemic sclerosis (dcSSc) is characterized by rapid changes in the skin and internal organs. The objective of this study was to develop a composite response index in dcSSc (CRISS) for use in randomized controlled trials (RCTs). Methods. We developed 150 paper patient profiles with standardized clinical outcome elements (core set items) using patients with dcSSc. Forty scleroderma experts rated 20 patient profiles each and assessed whether each patient had improved or not improved over a period of 1 year. Using the profiles for which raters had reached a consensus on whether the patients were improved versus not improved (79% of the profiles examined), we fit logistic regression models in which the binary outcome referred to whether the patient was improved or not, and the changes in the core set items from baseline to followup were entered as covariates. We tested the final index in a previously completed RCT. Results. Sixteen of 31 core items were included in the patient profiles after a consensus meeting and review of test characteristics of patient-level data. In the logistic regression model in which the included core set items were change over 1 year in the modified Rodnan skin thickness score, the forced vital capacity, the patient and physician global assessments, and the Health Assessment Questionnaire disability index, sensitivity was 0.982 (95% confidence interval 0.982-0.983) and specificity was 0.931 (95% confidence interval 0.930-0.932), and the model with these 5 items had the highest face validity. Subjects with a significant worsening of renal or cardiopulmonary involvement were classified as not improved, regardless of improvements in other core items. With use of the index, the effect of methotrexate could be differentiated from the effect of placebo in a 1-year RCT (P=0.02). Conclusion. We have developed a CRISS that is appropriate for use as an outcome assessment in RCTs of early dcSSc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available